Monopar Therapeutics Inc. (MNPR) is listed on NASDAQ in Pharmaceutical Stocks. It is $112.24, -1.49%, with a $753.4M market cap. RSI is 51.0, neutral. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 51.0 Neutral
Market Cap $753.4M
Volume 160.9K
Fundamentals — 10-Q Q2 2026
Revenue $0
Net Income $-9.2M
EPS --
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Tsuchimoto Kim R | Director | Sell | 4,090 | $111.39 | $455,567 | 2026 Aug 26 |
| Rioux Patrice | Insider | Sell | 1 | $111.26 | $111 | 2026 Aug 26 |
| Tsuchimoto Kim R | Director | Sell | 4,090 | $111.39 | $455,567 | 2026 Aug 26 |
| Anderson Raymond | Director | Sell | 3,142 | $111.98 | $351,835 | 2026 Aug 25 |
| Anderson Raymond | Director | Sell | 3,142 | $111.77 | $351,189 | 2026 Aug 25 |
| Vu Quan Anh | Chief Financial Officer | Buy | 1,500 | $69.95 | $104,925 | 2025 Dec 26 |
| Klausner Arthur J | Director | Sell | 5,121 | $67.15 | $343,889 | 2025 Dec 18 |
| Mazar Andrew Paul | Insider | Sell | 550,229 | $63.61 | $35.0M | 2025 Sep 24 |
| Robinson Chandler | Chief Executive Officer | Sell | 16,800 | $40.00 | $672,000 | 2025 Jul 14 |
| Tsuchimoto Kim R | Director | Sell | 8,904 | $40.00 | $356,160 | 2025 Jul 14 |
| Starr Christopher M | Director | Sell | 16,800 | $40.00 | $672,000 | 2025 Jul 14 |
| Mazar Andrew Paul | Insider | Sell | 33,334 | $35.00 | $1.2M | 2025 Apr 2 |
| Radhakrishnan Karthik | Chief Financial Officer | Buy | 1,550 | $16.25 | $25,188 | 2024 Oct 28 |
| Cittadine Andrew | Chief Operating Officer | Buy | 32,508 | $0.78 | $25,496 | 2024 Jun 20 |
| Cittadine Andrew | Chief Operating Officer | Buy | 36,000 | $0.91 | $32,880 | 2024 Jun 17 |
| Cittadine Andrew | Chief Operating Officer | Buy | 24,000 | $0.77 | $18,480 | 2024 Jun 4 |
| Cittadine Andrew | Chief Operating Officer | Buy | 36,000 | $0.64 | $23,040 | 2024 May 31 |
| Cittadine Andrew | Chief Operating Officer | Buy | 16,053 | $3.09 | $49,659 | 2022 Nov 15 |
| Mazar Andrew Paul | Chief Executive Officer | Sell | 125,000 | $14.64 | $1.8M | 2021 Feb 11 |
| Brown Michael J | Director | Buy | 125,000 | $8.00 | $1.0M | 2019 Dec 18 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
Take MNPR further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put MNPR in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Monopar Therapeutics Inc. next reports.
Set alerts on MNPR
Get notified when Monopar Therapeutics Inc. hits your price targets or technical conditions are met.
Get Started Free